OMER - Omeros awarded $6.69M grant from NIH for cocaine use disorder treatment
2023-04-10 10:13:43 ET
- –Omeros ( NASDAQ: OMER ) said it had been granted $6.69M from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop its lead proprietary PDE7 inhibitor, OMS527, to treat cocaine use disorder.
- The grant is for over three years and will support both preclinical cocaine interaction studies and a clinical study.
- Cocaine use disorder is a medical condition characterized by compulsive cocaine use.
- Press Release
For further details see:
Omeros awarded $6.69M grant from NIH for cocaine use disorder treatment